Contact Us

MIAMI, FL. SEPTEMBER 7, 2018 – ArisGlobal, LLC, a leading provider of integrated cloud-based software solutions for life sciences, will present a session titled, “The IoT of Pharmacovigilance: From Concept to Reality with Digital Technologies” at the upcoming 5th Annual Risk Management and Pharmacovigilance Summit to be held in Vienna from September 18-20, 2018.

Dr. Vivek Ahuja, Vice President, Global Pharmacovigilance, ArisGlobal, and an industry thought leader, will present the session, scheduled for September 19, 11:55 a.m. He will explore the scope of IoT technologies and allied technologies in pharmacovigilance, and share the expected impact this will have in the drug safety world.

Simply put, IoT is a network of devices with embedded sensors capable of machine-to-machine communication,” Dr. Ahuja explained. “Together with advanced computing technologies like artificial intelligence in pharmacovigilance systems and processes, the world of drug safety as we currently know it, is facing digital disruption that will create major transformation for the better. The barriers between passive and active pharmacovigilance can be dissolved and communication among all stakeholders including patients, healthcare providers, marketing authorization holders, and regulators can be enhanced.”

About ArisGlobal

ArisGlobal is a visionary technology company that’s transforming the way today’s most successful life sciences companies develop breakthroughs and bring new products to market. The ArisGlobal LifeSphere® cognitive technology platform integrates machine-learning capabilities to automate the core functions of the product lifecycle. Designed with deep expertise and a long-term perspective that spans more than 30 years, our cognitive platform delivers actionable insights, boosts efficiency, ensures compliance, and lowers total cost of ownership through multi-tenancy.

Headquartered in the United States, ArisGlobal has regional offices in Europe, India and Japan. For more information, visit or follow ArisGlobal on LinkedIn and Twitter.

Share This